Page Menu

Skin Cancer Clinical Trials

Skin cancer clinical trials are used to compare emerging, innovative treatments to the current standard of care. These trials offer a number of benefits, such as:

  • The ability to access new, promising drugs long before they are available in other settings
  • The ability to explore additional therapies when other treatments do not provide adequate benefits (as is often the case with late-stage cancers)
  • The ability to contribute to new developments that will eventually benefit thousands of patients who have been diagnosed with skin cancer

At Moffitt Cancer Center, our skin cancer clinical trials have tested some of the most promising developments in treatment to date. For instance, we’ve tested several forms of immunotherapy, intralesional therapy and molecular targeted therapy. Additionally, we’re one of the only centers in the country that has the protocol to test T-cell therapies, which boost the body’s natural ability to fight cancer using its own immune system.

When you participate in a clinical trial at Moffitt, you can expect to have your progress monitored by a team of oncologists who specialize in skin cancer. This way, we can ensure that you’re receiving an ideal dose of the treatment and that any side effects are kept to a minimum.

Depending on the protocol of your specific trial, you may also be able to receive additional treatments here at Moffitt Cancer Center. We’ll make sure that you’re receiving the treatments that are most appropriate for your specific diagnosis, and you’ll be able to access all of your treatments in one convenient location.

For more information about the skin cancer clinical trials offered at Moffitt,  call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form. No referral is required; our clinical trial navigators will help you determine whether you might benefit from a clinical trial, and will explain to you all of the requirements involved.

calledFromCancerPage=True - substr=
testProtocol=

Open Clinical Trials:

Showing of 50

CLINICAL TRIAL 18989

A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 19327

A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients with Metastatic Melanoma or Non-small Cell Lung Cancer with Untreated Brain Metastases

Disease Site: Non small cell lung cancer, Brain and Nervous System, Lung, Melanoma, skin, Gliomas

View Trial Details

CLINICAL TRIAL 19441

Pilot Study of Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 19495

A Multicenter, Randomized, Double Blinded, Placebo Controlled, Phase 3 trial of Adjuvant Avelumab (anti PDL1 antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases

Disease Site: Merkel cell carcinoma (neuroendocrine skin cancer), Other Skin

View Trial Details

CLINICAL TRIAL 19748

Phase II Randomized Trial of Radiotherapy with Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients with Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN Trial)

Disease Site: Head & Neck, Squamous Cell Carcinoma (SCC), Lip, Oral Cavity and Pharynx, Other Skin

View Trial Details

CLINICAL TRIAL 19967

A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma

Disease Site: Skin, Other Skin

View Trial Details

CLINICAL TRIAL 20040

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

Disease Site: Merkel cell carcinoma (neuroendocrine skin cancer), Other Skin

View Trial Details

CLINICAL TRIAL 20162

Phase 1 Trial of Intralesional Immunotherapy with IFx-Hu2.0 Vaccine in Patients with Advanced Merkel Cell Carcinoma or Cutaneous Squamous Cell Carcinoma

Disease Site: Melanoma, skin, Merkel cell carcinoma (neuroendocrine skin cancer), Other Skin, Skin, Squamous Cell Carcinoma (SCC)

View Trial Details

CLINICAL TRIAL 20270

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors (IOV-COM-202)

Disease Site: Lung, Melanoma, skin, Non small cell lung cancer

View Trial Details

CLINICAL TRIAL 20313

Neoadjuvant Immunotherapy with Intratumoral Tavokinogene Telseplasmid (Tavo) plus Electroporation in Combination with Intravenous Nivolumab in Patients with Operable Locally- Regionally Advanced Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 20490

Keystroke: A Randomized Phase II Study of Pembrolizumab (Keytruda) Plus Stereotactic Re-irradiation versus SBRT Alone For Locoregionally Recurrent or Second Primary Head and Neck Carcinoma

Disease Site: Other Skin

View Trial Details

CLINICAL TRIAL 20494

A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 20562

A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma

Disease Site: Other Skin, Skin, Squamous Cell Carcinoma (SCC)

View Trial Details

CLINICAL TRIAL 20641

A Randomized Pilot Trial of Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib and Binimetinib in Advanced Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 20731

Phase 2 Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Disease Site: Other Skin, Squamous Cell Carcinoma (SCC)

View Trial Details

CLINICAL TRIAL 20773

Neoadjuvant Lenvatinib Plus Pembrolizumab in Resectable Merkel Cell Carcinoma

Disease Site: Merkel cell carcinoma (neuroendocrine skin cancer), Other Skin

View Trial Details

CLINICAL TRIAL 20794

Neoadjuvant Cemiplimab in Stage I-II Merkel Cell Carcinoma: Safety and Biomarker Analysis

Disease Site: Other Skin

View Trial Details

CLINICAL TRIAL 20854

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Disease Site: Melanoma, skin, Other Skin

View Trial Details

CLINICAL TRIAL 20904

A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in Braf-V600 Mutant Melanoma with Brain Metastases

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 20956

A Two-Part, Phase 1a/B, Open-Label, Multicenter Trial Evaluating Pharmacokinetics, Safety and Efficacy Of PF-07284890 (ARRY-461) In Participants With BRAF V600-Mutant Solid Tumors With And Without Brain Involvement

Disease Site: Any Site, Brain and Nervous System, Larynx, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Skin, Brain metastasis, Gliomas

View Trial Details

CLINICAL TRIAL 21112

Phase 2 Study of Axitinib + Ipilimumab in Advanced Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 21163

A Phase 1/2 Study of Regn7075 (Egfrxcd28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors

Disease Site: Anus, Breast, Cervix, Colon, Esophagus, Kidney, Lip, Oral Cavity and Pharynx, Lung, Other Digestive Organ, Other Female Genital, Other Male Genital, Other Skin, Other Urinary, Pancreas, Prostate, Stomach

View Trial Details

CLINICAL TRIAL 21179

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects with Advanced Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 21180

A First-in-Human, Two-Part, Open-Label, Clinical Study to Assess the Safety, Tolerability and Activity of Intravenous Doses of ICT01 as Monotherapy and in Combination with an Immune Checkpoint Inhibitor, in Patients with Advanced-Stage, Relapsed/Refractory Cancer (EVICTION Study)

Disease Site: Any Site, Breast, Colon, Larynx, Leukemia, other, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Ovary, Prostate, Stomach, Urinary Bladder

View Trial Details

CLINICAL TRIAL 21239

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 21344

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients with Melanoma (Morpheus-Melanoma)

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 21573

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients with Hepatic Dominant Ocular Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 90015

Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

Disease Site: Breast, Lung, Melanoma, skin, Ovary, Pancreas, Urinary Bladder

View Trial Details

CLINICAL TRIAL 20256

CemiplimAb Survivorship Epidemiology (CASE) Study

Disease Site: Squamous Cell Carcinoma (SCC), Other Skin

View Trial Details

CLINICAL TRIAL 21183

The EDUCATE Initiative A Multimodal Campaign to Enhance Provider-Patient Awareness of CTCL Disparities in Skin of Color

Disease Site: Other Skin

View Trial Details

CLINICAL TRIAL 19950

Linking the Skin and Gut Microbiome to Immunosuppression in Skin Cancer

Disease Site: Other Skin

View Trial Details

CLINICAL TRIAL 21125

MElanoma Research Lymph Node Prediction Implementation National_001 (MERLIN_001)

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 50401

Creation of Cell Lines and Corresponding DNA and RNA Analysis from Acral Lentiginous Malignant Melanoma

Disease Site: Melanoma, skin

View Trial Details